Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
ID | DOID:60079 |
Name | Her2-receptor positive breast cancer |
Definition | A breast cancer that is characterized by the presence of Her2 receptors. |
Source | DiseaseOntology.org |
Alt Ids | |
Path | disease disease of cellular proliferation cancer organ system cancer thoracic cancer breast cancer Her2-receptor positive breast cancer |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|---|---|---|---|
PIK3CA wild-type | Buparlisib + Trastuzumab | Her2-receptor positive breast cancer | predicted - sensitive | detail... |
PIK3CA mutant | CCT128930 | Her2-receptor positive breast cancer | sensitive | detail... |
FGFR1 amp | Dovitinib | Her2-receptor positive breast cancer | sensitive | detail... |
FGFR2 amp | Dovitinib | Her2-receptor positive breast cancer | sensitive | detail... |
PIK3CA wild-type | Lapatinib + Paclitaxel + Trastuzumab | Her2-receptor positive breast cancer | sensitive | detail... |
PIK3CA mutant | Ado-trastuzumab emtansine | Her2-receptor positive breast cancer | not predictive | detail... |
PIK3CA H1047R | STX-478 | Her2-receptor positive breast cancer | sensitive | detail... |
PIK3CA E542K | STX-478 | Her2-receptor positive breast cancer | sensitive | detail... |
PIK3CA H1047R | ZM-PI05 | Her2-receptor positive breast cancer | sensitive | detail... |
PIK3CA C420R | ZM-PI05 | Her2-receptor positive breast cancer | sensitive | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT00411788 | Phase II | Sirolimus + Trastuzumab | A Phase II Study of Rapamycin and Trastuzumab for Patients With HER-2 Receptor Positive Metastatic Breast Cancer | Completed | USA | 0 |
NCT00574587 | Phase Ib/II | Paclitaxel + Vorinostat Trastuzumab Cyclophosphamide + Doxorubicin | Trial for Locally Advanced Her2 Positive Breast Cancer Using Paclitaxel, Trastuzumab, Doxorubicin and Cyclophasmide on a Weekly Basis | Completed | USA | 0 |
NCT01016886 | Phase Ib/II | Bisoprolol Perindopril | Multidisciplinary Approach to Novel Therapies in Cardiology Oncology Research | Unknown status | CAN | 0 |
NCT01118975 | Phase Ib/II | Lapatinib + Vorinostat | GCC 0845:Vorinostat and Lapatinib in Advanced Solid Tumors and Advanced Breast Cancer to Evaluate Response and Biomarkers | Terminated | USA | 0 |
NCT01160211 | Phase III | Lapatinib + Trastuzumab Letrozole Anastrozole Lapatinib Trastuzumab Exemestane | A Study to Compare the Safety and Efficacy of an Aromatase Inhibitor in Combination With Lapatinib, Trastuzumab or Both for the Treatment of Hormone Receptor Positive, HER2+ Metastatic Breast Cancer | Completed | USA | TUR | ROU | POL | NOR | LTU | ITA | ISR | IRL | HUN | HRV | GRC | GBR | FRA | ESP | DEU | CAN | BRA | BGR | BEL | AUS | ARG | 16 |
NCT01177397 | Phase Ib/II | Onatasertib | Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma | Completed | USA | GBR | FRA | ESP | 0 |
NCT01273610 | Phase II | Lapatinib + Trastuzumab | Tolerability of the Combination of Lapatinib and Trastuzumab in Adults Age 60 or Older With HER2 Positive Locally Advanced or Metastatic Breast Cancer | Active, not recruiting | USA | 0 |
NCT01276041 | Phase II | Paclitaxel + Pertuzumab + Trastuzumab | Paclitaxel, Trastuzumab, and Pertuzumab in the Treatment of Metastatic HER2-Positive Breast Cancer | Completed | USA | 0 |
NCT01300962 | Phase I | Buparlisib + Capecitabine + Lapatinib Buparlisib + Capecitabine + Trastuzumab Buparlisib + Capecitabine Alpelisib + Capecitabine | Study of BKM120 or BYL719 and Capecitabine in Patients With Metastatic Breast Cancer | Completed | USA | 0 |
NCT01305941 | Phase II | Everolimus + Trastuzumab + Vinorelbine | A Study Of Everolimus, Trastuzumab And Vinorelbine In HER2-Positive Breast Cancer Brain Metastases | Completed | USA | 0 |
NCT01325207 | Phase Ib/II | Trastuzumab | Intrathecal Trastuzumab for Leptomeningeal Metastases in HER2+ Breast Cancer | Completed | USA | 0 |
NCT01358877 | Phase III | Pertuzumab Epirubicin Cyclophosphamide Paclitaxel Docetaxel Trastuzumab Fluorouracil Carboplatin Doxorubicin | A Study of Pertuzumab in Addition to Chemotherapy and Trastuzumab as Adjuvant Therapy in Participants With Human Epidermal Growth Receptor 2 (HER2)-Positive Primary Breast Cancer (APHINITY) | Active, not recruiting | USA | SWE | SVN | ROU | POL | NZL | NLD | ITA | ISR | IRL | HUN | HRV | GBR | FRA | ESP | DNK | DEU | CZE | CHE | CAN | BGR | BEL | AUT | AUS | ARG | 17 |
NCT01434303 | Phase I | Entinostat + Lapatinib + Trastuzumab | Entinostat, Lapatinib Ditosylate and Trastuzumab in Treating Patients With Locally Recurrent or Distant Relapsed Metastatic Breast Cancer Previously Treated With Trastuzumab Only | Completed | USA | 0 |
NCT01491737 | Phase II | Anastrozole Letrozole Trastuzumab Pertuzumab + Trastuzumab | A Study of Pertuzumab in Combination With Trastuzumab Plus an Aromatase Inhibitor in Participants With Metastatic Human Epidermal Growth Factor Receptor 2 (HER2)-Positive and Hormone Receptor-Positive Advanced Breast Cancer (PERTAIN) | Completed | USA | TUR | ITA | GBR | FRA | ESP | BRA | 1 |
NCT01494662 | Phase II | Capecitabine + Neratinib Neratinib | HKI-272 for HER2-Positive Breast Cancer and Brain Metastases | Active, not recruiting | USA | 0 |
NCT01513083 | Phase I | Ado-trastuzumab emtansine | A Study of Trastuzumab Emtansine in Patients With HER2-Positive Metastatic Breast Cancer and Normal or Reduced Hepatic Function | Completed | USA | ITA | FRA | ESP | CAN | 0 |
NCT01526473 | Phase I | AVX901 | A Phase I Study To Evaluate The Antitumor Activity And Safety Of AVX901 | Completed | USA | 0 |
NCT01565083 | Phase II | Pertuzumab + Trastuzumab + Vinorelbine | A Study of Pertuzumab in Combination With Herceptin (Trastuzumab) And Vinorelbine in First Line in Patients With Metastatic or Locally Advanced HER2-Positive Breast Cancer | Completed | USA | ITA | FRA | ESP | DNK | DEU | BRA | 0 |
NCT01566721 | Phase III | Trastuzumab | A Safety and Tolerability Study of Assisted- and Self-Administered Subcutaneous Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With Early HER2-Positive Breast Cancer (SafeHer) | Completed | TUR | SWE | SVN | SVK | ROU | POL | NZL | NOR | NLD | LTU | ITA | IRL | HUN | HRV | GRC | GBR | FRA | ESP | DEU | CZE | CHE | CAN | BRA | BGR | AUS | ARG | 33 |
NCT01602406 | Phase I | Elgemtumab + Trastuzumab | Phase I Study LJM716 Combined With Trastuzumab in Patients With HER2 Overexpressing Metastatic Breast or Gastric Cancer | Completed | USA | NLD | ITA | GBR | FRA | ESP | BEL | 2 |
NCT01622868 | Phase II | Lapatinib | Whole-Brain Radiation Therapy or Stereotactic Radiosurgery With or Without Lapatinib Ditosylate in Treating Patients With Brain Metastasis From HER2-Positive Breast Cancer | Completed | USA | CAN | 1 |
NCT01702558 | Phase II | Ado-trastuzumab emtansine Ado-trastuzumab emtansine + Capecitabine | A Combination Study of Kadcyla (Trastuzumab Emtansine) and Capecitabine in Patients With HER2-Positive Metastatic Breast Cancer and Patients With HER2-Positive Locally Advanced / Metastatic Gastric Cancer | Terminated | SVK | ITA | GRC | FRA | ESP | DEU | CAN | BRA | ARG | 3 |
NCT01702571 | Phase III | Ado-trastuzumab emtansine | A Study of Trastuzumab Emtansine in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer Who Have Received Prior Anti-HER2 And Chemotherapy-based Treatment | Completed | TUR | SWE | SVN | SVK | POL | NOR | NLD | LUX | ITA | ISL | IRL | HUN | HRV | GRC | GBR | FRA | FIN | EST | ESP | DNK | DEU | CAN | BRA | BGR | BEL | AUT | AUS | ARG | 15 |
NCT01730118 | Phase I | HER2 Vaccine | Ad/HER2/Neu Dendritic Cell Cancer Vaccine Testing | Completed | USA | 0 |
NCT01772472 | Phase III | Ado-trastuzumab emtansine Trastuzumab | A Study of Trastuzumab Emtansine Versus Trastuzumab as Adjuvant Therapy in Patients With HER2-Positive Breast Cancer Who Have Residual Tumor in the Breast or Axillary Lymph Nodes Following Preoperative Therapy (KATHERINE) | Completed | USA | TUR | SWE | ITA | ISR | IRL | GRC | GBR | FRA | ESP | DEU | CZE | CHE | CAN | BRA | BEL | AUT | ARG | 10 |
NCT01783756 | Phase Ib/II | Capecitabine + Everolimus + Lapatinib | Phase 1b/2 Trial Using Lapatinib, Everolimus and Capecitabine for Treatment of HER-2 Positive Breast Cancer With CNS Metastasis | Completed | USA | 0 |
NCT01796197 | Phase II | Cyclophosphamide + Doxorubicin Pertuzumab + Trastuzumab Paclitaxel | Paclitaxel + Trastuzumab + Pertuzumab as Pre-Op for Inflammatory BrCa | Active, not recruiting | USA | 0 |
NCT01808573 | Phase III | Capecitabine + Lapatinib Capecitabine + Neratinib | A Study of Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer Who Have Received Two or More Prior HER2 Directed Regimens in the Metastatic Setting (NALA) | Completed | USA | TUR | SWE | NLD | ITA | ISR | IRL | GBR | FRA | FIN | ESP | DNK | DEU | CZE | CHE | CAN | BRA | BEL | AUT | AUS | ARG | 7 |
NCT01816035 | Phase I | Ado-trastuzumab emtansine | Ado-Trastuzumab Emtansine in Treating Patients With HER2-Positive Metastatic or Locally Advanced Breast Cancer That Cannot Be Removed by Surgery | Completed | USA | 0 |
NCT01817452 | Phase II | Pertuzumab + Trastuzumab Paclitaxel + Pertuzumab + Trastuzumab | A Prospective, Randomized Multicenter, Open-label Comparison of Preoperative Combination of Trastuzumab and Pertuzumab With or Without Concurrent Taxane Chemotherapy Given for Twelve Weeks in Patients With Operable HER2+/HR- Breast Cancer Within the ADAPT Protocol (ADAPT) | Active, not recruiting | DEU | 0 |
NCT01828021 | Phase II | Margetuximab-cmkb | Phase 2 Study of the Monoclonal Antibody MGAH22(Margetuximab)in Patients With Relapsed or Refractory Advanced Breast Cancer | Completed | USA | 0 |
NCT01848756 | Phase Ib/II | SNX-5422 | Safety and Efficacy of SNX-5422 in Human Epidermal Growth Factor Receptor 2 (HER2) Positive Cancers | Terminated | USA | 0 |
NCT01853748 | Phase II | Paclitaxel + Trastuzumab Ado-trastuzumab emtansine | T-DM1 vs Paclitaxel/Trastuzumab for Breast (ATEMPT Trial) | Active, not recruiting | USA | 0 |
NCT01855828 | Phase II | Paclitaxel + Pertuzumab + Trastuzumab Cyclophosphamide + Epirubicin + Fluorouracil + Pertuzumab + Trastuzumab | Phase 2 Trial of Pertuzumab and Trastuzumab With Weekly Paclitaxel and Chemotherapy for HER2 Positive Breast Cancer | Completed | USA | 0 |
NCT01873833 | Phase II | Capecitabine + Cyclophosphamide + Lapatinib + Trastuzumab | Capecitabine, Cyclophosphamide, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With HER2-Positive Metastatic Breast Cancer | Terminated | USA | 0 |
NCT01875666 | Phase I | Lapatinib + Trastuzumab Trastuzumab Pertuzumab Pertuzumab + Trastuzumab | Defining the HER2 Positive (+) Breast Cancer Kinome Response to Trastuzumab, Pertuzumab, Combination Trastuzumab +Pertuzumab, or Combination Trastuzumab + Lapatinib | Completed | USA | 0 |
NCT01901146 | Phase III | Cyclophosphamide + Epirubicin Paclitaxel + Trastuzumab | Efficacy and Safety Study of ABP 980 Compared With Trastuzumab in Subjects With HER2 Positive Early Breast Cancer (Lilac) | Completed | ROU | POL | ITA | HUN | GRC | GBR | ESP | DEU | CAN | BRA | BGR | 7 |
NCT01904903 | Phase II | Pertuzumab Ado-trastuzumab emtansine Trastuzumab | Cardiac Safety Study in Patients With HER2+ Breast Cancer (SAFE-HEaRt) | Completed | USA | 0 |
NCT01912963 | Phase II | Eribulin Pertuzumab Trastuzumab | Phase II Study of Eribulin Mesylate, Trastuzumab, and Pertuzumab in Women With Metastatic, Unresectable Locally Advanced, or Locally Recurrent HER2-Positive Breast Cancer | Terminated | USA | 0 |
NCT01921335 | Phase I | Trastuzumab + Tucatinib | ARRY-380 + Trastuzuamab for Breast w/ Brain Mets | Completed | USA | 0 |
NCT01922921 | Phase Ib/II | HER-2/neu intracellular domain protein + Pertuzumab + Polysaccharide-K + Trastuzumab HER-2/neu intracellular domain protein + Pertuzumab + Trastuzumab | Vaccine Therapy With or Without Polysaccharide-K in Treating Patients With Stage IV HER2 Positive Breast Cancer Receiving HER2-Targeted Monoclonal Antibody Therapy | Completed | USA | 0 |
NCT01924351 | Phase II | HER2-positive Breast Cancer With Brain Metastasis (GCC 1345) | Withdrawn | USA | 0 | |
NCT01934894 | Phase II | Cabazitaxel + Lapatinib | Cabazitaxel Plus Lapatinib as Therapy for HER2-Positive Metastatic Breast Cancer Patients With Intracranial Metastases | Terminated | USA | 0 |
NCT01937117 | Phase II | Pertuzumab + Trastuzumab | Pertuzumab and Trastuzumab as Neoadjuvant Treatment in Patients With HER2-Positive Breast Cancer | Active, not recruiting | USA | 0 |
NCT01966471 | Phase III | Cyclophosphamide + Docetaxel + Doxorubicin + Epirubicin + Fluorouracil + Paclitaxel + Pertuzumab + Trastuzumab Cyclophosphamide + Doxorubicin + Epirubicin + Fluorouracil + Pertuzumab + Trastuzumab | A Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a Taxane Following Anthracyclines as Adjuvant Therapy in Participants With Operable HER2-Positive Primary Breast Cancer | Completed | USA | SWE | ROU | POL | NOR | ITA | ISR | HUN | GBR | FRA | ESP | DEU | CZE | CHE | CAN | BRA | BEL | AUS | 18 |
NCT01976169 | Phase I | Ado-trastuzumab emtansine + Palbociclib | Phase 1b Study of PD-0332991 in Combination With T-DM1(Trastuzumab-DM1) | Completed | USA | 0 |
NCT01983501 | Phase I | Ado-trastuzumab emtansine + Tucatinib | A Phase 1b Study of ONT-380 Combined With Ado-trastuzumab Emtansine (T-DM1) in Patients With HER2+ Breast Cancer | Completed | USA | CAN | 0 |
NCT01989676 | Phase III | Paclitaxel + Trastuzumab Paclitaxel + Trazimera | A Study Of PF-05280014 [Trastuzumab-Pfizer] Or Herceptin® [Trastuzumab-EU] Plus Paclitaxel In HER2 Positive First Line Metastatic Breast Cancer Treatment (REFLECTIONS B327-02) | Completed | USA | TUR | SVK | ROU | POL | LVA | HUN | GRC | CZE | BRA | ARG | 13 |
NCT02000596 | Phase II | Pertuzumab + Trastuzumab Anastrozole + Fulvestrant | Trastuzmab and Pertuzumab Alone or in Combination With Hormonal Therapy or Chemotherapy With Eribulin in Women Aged 60 and Over With HER2/Neu Overexpressed Locally Advanced or MBC | Terminated | USA | 0 |
NCT02003209 | Phase III | Carboplatin + Docetaxel + Goserelin + Pertuzumab + Trastuzumab Carboplatin + Docetaxel + Pertuzumab + Trastuzumab | Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer | Active, not recruiting | USA | 1 |
NCT02014909 | Phase I | CDX-3379 CDX-3379 + Vemurafenib CDX-3379 + Trastuzumab CDX-3379 + Cetuximab CDX-3379 + Erlotinib | A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of KTN3379 in Adult Subjects With Advanced Tumors | Completed | USA | 0 |
NCT02025192 | Phase I | Capecitabine + Trastuzumab + Tucatinib Trastuzumab + Tucatinib Capecitabine + Tucatinib | A Study of Tucatinib (ONT-380) Combined With Capecitabine and/or Trastuzumab in Patients With HER2+ Metastatic Breast Cancer | Completed | USA | 0 |
NCT02038010 | Phase I | Ado-trastuzumab emtansine + Alpelisib | BYL719 + T-DM1 in HER2(+) Metastatic Breast Cancer Pts Who Progress on Prior Trastuzumab & Taxane Tx | Completed | USA | 0 |
NCT02057133 | Phase I | Abemaciclib + Loperamide + Pertuzumab + Trastuzumab Abemaciclib + Fulvestrant + LY3023414 Abemaciclib + Letrozole Abemaciclib + Exemestane Abemaciclib Abemaciclib + Everolimus + Exemestane Abemaciclib + Anastrozole Abemaciclib + Tamoxifen Abemaciclib + Trastuzumab | A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread | Active, not recruiting | USA | 0 |
NCT02060253 | Phase I | Ganetespib + Paclitaxel + Trastuzumab | Ganetespib, Paclitaxel and Trastuzumab for Advanced or Metastatic Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Breast Cancer | Completed | USA | 0 |
NCT02061332 | Phase Ib/II | HER2-pulsed DC1 vaccine | DC Vaccine for Patients With Ductal Carcinoma In Situ | Completed | USA | 0 |
NCT02063724 | Phase I | HER2-pulsed DC1 vaccine | HER-2 Pulsed DC Vaccine to Prevent Recurrence of Invasive Breast Cancer (Adjuvant) | Completed | USA | 0 |
NCT02066532 | Phase Ib/II | Ruxolitinib + Trastuzumab | Ruxolitinib in Combination With Trastuzumab in Metastatic HER2 Positive Breast Cancer | Completed | USA | 0 |
NCT02073487 | Phase II | Paclitaxel Ado-trastuzumab emtansine + Lapatinib Lapatinib + Trastuzumab Nab-paclitaxel | Neoadjuvant TDM1 With Lapatinib and Abraxane Compared With Trastuzumab With Lapatinib and Paclitaxel | Completed | USA | 0 |
NCT02073916 | Phase I | Ado-trastuzumab emtansine + Lapatinib + Nab-paclitaxel | TDM1 With Abraxane and Lapatinib for Metastatic HER2 Positive Breast Cancer | Completed | USA | 0 |
NCT02091960 | Phase II | Enzalutamide + Trastuzumab | A Study to Assess the Efficacy and Safety of Enzalutamide With Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2 Positive (HER2+), Androgen Receptor Positive (AR+) Metastatic or Locally Advanced Breast Cancer | Completed | USA | ITA | GBR | ESP | CAN | BEL | 0 |
NCT02131064 | Phase III | Ado-trastuzumab emtansine + Pertuzumab Carboplatin + Docetaxel + Pertuzumab + Trastuzumab | A Study Comparing Kadcyla Plus Perjeta Treatment to Chemotherapy Combined With Herceptin Plus Perjeta in Patients With HER2-Positive Breast Cancer | Completed | USA | FRA | ESP | DEU | CAN | BEL | 4 |
NCT02132949 | Phase II | Pertuzumab + Trastuzumab Cyclophosphamide + Doxorubicin + Paclitaxel + Pertuzumab + Trastuzumab Cyclophosphamide + Docetaxel + Epirubicin + Fluorouracil + Pertuzumab + Trastuzumab | A Study Evaluating Pertuzumab (Perjeta) Combined With Trastuzumab (Herceptin) and Standard Anthracycline-based Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced, Inflammatory, or Early-stage Breast Cancer | Completed | USA | POL | NOR | ITA | GBR | FRA | ESP | DNK | DEU | CAN | 2 |
NCT02139358 | Phase Ib/II | Gemcitabine + Pertuzumab + Trastuzumab | Phase I/IIa Trial of Gemcitabine Plus Trastuzumab and Pertuzumab in Previously Treated Metastatic HER2+ Breast Cancer | Completed | USA | 0 |
NCT02152943 | Phase I | Everolimus + Letrozole + Trastuzumab | Everolimus, Letrozole and Trastuzumab in HR- and HER2/Neu-positive Patients | Completed | USA | 0 |
NCT02154529 | Phase Ib/II | Tesevatinib + Trastuzumab | Study of the Combination of KD019 and Trastuzumab in Subjects With HER2-Positive Metastatic Breast Cancer | Terminated | USA | 0 |
NCT02167854 | Phase I | Alpelisib + Elgemtumab + Trastuzumab | Open-Label Study Evaluating the Safety and Tolerability of LJM716, BYL719 and Trastuzumab in Patients With Metastatic HER2+ Breast Cancer | Completed | USA | 0 |
NCT02187744 | Phase III | Carboplatin + Docetaxel + Trastuzumab | A Study Of PF-05280014 Or Trastuzumab Plus Taxotere® And Carboplatin In HER2 Positive Breast Cancer In The Neoadjuvant Setting (REFLECTIONS B327-04) | Completed | USA | SVK | POL | ITA | HUN | CZE | 4 |
NCT02213042 | Phase II | Lapatinib + Trastuzumab Trastuzumab | Evaluation of Biomarkers Associated With Response to Subsequent Therapies in Subjects With HER2-Positive Metastatic Breast Cancer | Terminated | USA | ITA | ESP | BRA | AUT | ARG | 6 |
NCT02213744 | Phase II | Trastuzumab + Vinorelbine Capecitabine + Trastuzumab Gemcitabine + Trastuzumab MM-302 + Trastuzumab | MM-302 Plus Trastuzumab vs. Chemotherapy of Physician's Choice Plus Trastuzumab in HER2-Positive Locally Advanced/Metastatic Breast Cancer Patients | Terminated | USA | ITA | FRA | ESP | DEU | CAN | BEL | AUT | 1 |
NCT02229149 | Phase II | Paclitaxel Docetaxel Pertuzumab + Trastuzumab Nab-paclitaxel Vinorelbine Trastuzumab Capecitabine | Phase 2 Study of Standard Chemotherapy With Trastuzumab, Plus or Minus Pertuzumab, for Pre-treated Metastatic Breast Cancer | Terminated | USA | 0 |
NCT02236000 | Phase Ib/II | Ado-trastuzumab emtansine + Neratinib | A Dose-Escalation Study Evaluating the Combination of Trastuzumab Emtansine (T-DM1) With Neratinib in Women With Metastatic HER2-Positive Breast Cancer | Completed | USA | 0 |
NCT02252887 | Phase II | Gemcitabine + Pertuzumab + Trastuzumab | Gemcitabine, Trastuzumab, and Pertuzumab in the Treatment of Metastatic HER2-Positive Breast Cancer After Prior Trastuzumab/Pertuzumab, or Pertuzumab Based Therapy | Active, not recruiting | USA | 0 |
NCT02297230 | Phase Ib/II | Capecitabine Paclitaxel Paclitaxel + Trastuzumab | Locally Advanced Breast Cancer: Individualized Treatment Based On Tumor Molecular Characteristics | Terminated | USA | 0 |
NCT02297698 | Phase II | Sargramostim Trastuzumab E75 | Phase II Trial of Combination Immunotherapy With NeuVax and Trastuzumab in High-risk HER2+ Breast Cancer Patients | Completed | USA | 0 |
NCT02308020 | Phase II | Abemaciclib | A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer, Non-small Cell Lung Cancer, or Melanoma That Has Spread to the Brain | Completed | USA | ITA | ISR | FRA | ESP | CAN | BEL | AUT | AUS | 0 |
NCT02318901 | Phase Ib/II | Ado-trastuzumab emtansine + Pembrolizumab Pembrolizumab + Trastuzumab Cetuximab + Pembrolizumab | Pembrolizumab and Monoclonal Antibody Therapy in Advanced Cancer | Terminated | USA | 0 |
NCT02326974 | Phase II | Ado-trastuzumab emtansine + Pertuzumab | T-DM1+Pertuzumab in Pre-OP Early-Stage HER2+ BRCA | Active, not recruiting | USA | 0 |
NCT02336984 | Phase Ib/II | Trastuzumab HER2-pulsed DC1 vaccine | A Phase I/II Trial of HER-2/Neu Pulsed DC1 Vaccine Combined With Trastuzumab for Patients With DCIS | Withdrawn | USA | 0 |
NCT02344472 | Phase III | Fulvestrant + Pertuzumab + Ribociclib + Trastuzumab Paclitaxel + Pertuzumab + Trastuzumab Docetaxel + Pertuzumab + Trastuzumab Capecitabine + Pertuzumab + Trastuzumab Exemestane + Pertuzumab + Ribociclib + Trastuzumab Letrozole + Pertuzumab + Ribociclib + Trastuzumab Eribulin + Pertuzumab + Trastuzumab Anastrozole + Pertuzumab + Ribociclib + Trastuzumab Goserelin + Pertuzumab + Ribociclib + Trastuzumab Pertuzumab + Trastuzumab + Vinorelbine Nab-paclitaxel + Pertuzumab + Trastuzumab Leuprolide + Pertuzumab + Ribociclib + Trastuzumab | Detect V / CHEVENDO (Chemo vs. Endo) | Active, not recruiting | DEU | 0 |
NCT02345772 | Phase I | Fulvestrant Docetaxel + Pertuzumab + Trastuzumab | Neoadjuvant Hormonal Therapy Combined With Chemoimmunotherapy (Taxotere, Trastuzumab and Pertuzumab) in Patients With HER2-positive and ER-Positive Breast Cancer | Terminated | USA | 0 |
NCT02390427 | Phase I | Trastuzumab Paclitaxel Pertuzumab Taselisib | Phase Ib Dose-escalation Trial of Taselisib (GDC-0032) in Combination With Anti-HER2 Therapies in Participants With Advanced HER2+ Breast Cancer | Completed | USA | 0 |
NCT02402712 | Phase III | Docetaxel + Pertuzumab + Trastuzumab | Phase IIIb Study to Evaluate the Safety and Tolerability of Herceptin SC With Perjeta and Docetaxel in Patients With HER2-positive Advanced Breast Cancer | Completed | POL | ITA | HUN | GBR | FRA | ESP | DEU | CAN | BGR | BEL | 2 |
NCT02403271 | Phase Ib/II | Durvalumab + Ibrutinib | A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Solid Tumors | Completed | USA | 0 |
NCT02448420 | Phase II | Eribulin + Trastuzumab Fulvestrant + Palbociclib + Trastuzumab Ado-trastuzumab emtansine + Trastuzumab Palbociclib + Tamoxifen + Trastuzumab Anastrozole + Palbociclib + Trastuzumab Capecitabine + Trastuzumab Gemcitabine + Trastuzumab Palbociclib + Trastuzumab Exemestane + Palbociclib + Trastuzumab Trastuzumab + Vinorelbine Letrozole + Palbociclib + Trastuzumab | Study of Palbociclib and Trastuzumab With Endocrine Therapy in HER2-positive Metastatic Breast Cancer (PATRICIA II) | Completed | ESP | 0 |
NCT02492711 | Phase III | Vinorelbine Capecitabine Gemcitabine Trastuzumab Eribulin Margetuximab-cmkb | Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast Cancer | Completed | USA | POL | NLD | ITA | ISR | GBR | FRA | FIN | ESP | DNK | DEU | CZE | CAN | BEL | AUT | 3 |
NCT02500199 | Phase I | Pyrotinib | Phase I Study of Pyrotinib in Patients With HER2-positive Solid Tumors | Unknown status | USA | 0 |
NCT02536339 | Phase II | Pertuzumab + Trastuzumab | A Study of Pertuzumab With High-Dose Trastuzumab for the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer (MBC) With Central Nervous System (CNS) Progression Post-Radiotherapy | Completed | USA | 0 |
NCT02571530 | Phase I | Trastuzumab | Super-selective Intra-arterial Cerebral Infusion of Trastuzumab for the Treatment of Cerebral Metastases of HER2/Neu Positive Breast Cancer | Terminated | USA | 0 |
NCT02598427 | Phase I | Pertuzumab + Trastuzumab | Intrathecal Pertuzumab and Trastuzumab in Patients With New Untreated Asymptomatic or Low Symptomatic Brain Metastasis in HER2 Positive Breast Cancer | Terminated | USA | 0 |
NCT02605915 | Phase I | Atezolizumab + Trastuzumab Docetaxel Carboplatin Pertuzumab | Safety and Pharmacokinetics of Atezolizumab in Combination With Trastuzumab Emtansine or With Trastuzumab and Pertuzumab in Participants With HER2-Positive Breast Cancer | Completed | USA | 0 |
NCT02614794 | Phase II | Capecitabine + Trastuzumab + Tucatinib Capecitabine + Trastuzumab | A Study of Tucatinib vs. Placebo in Combination With Capecitabine & Trastuzumab in Patients With Advanced HER2+ Breast Cancer (HER2CLIMB) | Completed | USA | ITA | ISR | GBR | FRA | ESP | DNK | DEU | CZE | CHE | CAN | BEL | AUT | AUS | 1 |
NCT02649686 | Phase I | Durvalumab + Trastuzumab | Durvalumab in Patients With HER-2 Positive Metastatic Breast Cancer Receiving Trastuzumab | Completed | CAN | 0 |
NCT02650752 | Phase I | Capecitabine + Lapatinib | Intermittent High-Dose Lapatinib in Tandem With Capecitabine for HER2 Overexpressed/Amplified Metastatic Breast Cancer With Central Nervous System (CNS) Metastases | Completed | USA | 0 |
NCT02654119 | Phase II | Cyclophosphamide + Paclitaxel + Trastuzumab | Cyclophosphamide, Paclitaxel, and Trastuzumab in Treating Stage I-II HER2/Neu Positive Breast Cancer After Surgery | Active, not recruiting | USA | 0 |
NCT02657343 | Phase Ib/II | Ribociclib Trastuzumab Ado-trastuzumab emtansine | An Open-Label, Phase Ib/II Clinical Trial Of Cdk 4/6 Inhibitor, Ribociclib (Lee011), In Combination With Trastuzumab Or T-Dm1 For Advanced/Metastatic Her2-Positive Breast Cancer. | Completed | USA | 0 |
NCT02658084 | Phase Ib/II | Ado-trastuzumab emtansine + Vinorelbine | Vinorelbine With Trastuzumab Emtansine in Pre-Treated HER2-Positive Metastatic Breast Cancer | Terminated | USA | 0 |
NCT02659514 | Phase II | Poziotinib | Study of Poziotinib in Patients With HER2-Positive Metastatic Breast Cancer | Completed | USA | 0 |
NCT02673398 | Phase II | Neratinib | Neratinib in Treating Older Patients With Stage IV HER2-Positive Breast Cancer | Completed | USA | 0 |
NCT02675231 | Phase II | Trastuzumab Abemaciclib + Trastuzumab Abemaciclib + Fulvestrant + Trastuzumab | A Study of Abemaciclib (LY2835219) in Women With HR+, HER2+ Locally Advanced or Metastatic Breast Cancer (monarcHER) | Completed | USA | ITA | GRC | GBR | FRA | ESP | DEU | CAN | BRA | BEL | AUS | ARG | 2 |
NCT02689921 | Phase II | Anastrozole Letrozole Leuprolide Pertuzumab + Trastuzumab Exemestane | NEOADjuvant Aromatase Inhibitor and Pertuzumab/Trastuzumab for Women With Breast Cancer (NEOADAPT) | Unknown status | USA | 0 |
NCT02751528 | Phase I | ETBX-021 | QUILT-3.013: Study of Ad5 [E1-, E2b-]-HER2/Neu Vaccine (ETBX-021) in Subjects With Unresectable Locally Advanced or Metastatic HER2-Expressing Breast Cancer | Unknown status | USA | 0 |
NCT02774681 | Phase II | Trastuzumab Palbociclib | Palbociclib in Treating Patients With Metastatic HER-2 Positive Breast Cancer With Brain Metastasis | Terminated | USA | 0 |
NCT02789657 | Phase II | Carboplatin + Paclitaxel + Pertuzumab + Trastuzumab Cyclophosphamide + Doxorubicin | Neoadjuvant Therapy in Clinical Stage I-III HER2-positive Breast Cancer. | Completed | USA | 0 |
NCT02827877 | Phase II | Pertuzumab + Trastuzumab | Cu64-DOTA-trastuzumab PET and Markers Predicting Response to Neoadjuvant Trastuzumab + Pertuzum in HER2+ Breast Cancer | Active, not recruiting | USA | 0 |
NCT02892123 | Phase I | Capecitabine + ZW25 ZW25 Paclitaxel + ZW25 Vinorelbine + ZW25 | Trial of ZW25 (Zanidatamab) in Patients With Advanced HER2-expressing Cancers | Active, not recruiting | USA | CAN | 1 |
NCT02907918 | Phase II | Goserelin Letrozole + Palbociclib + Trastuzumab | Neoadjuvant Study of Palbociclib in Combination With Letrozole and Trastuzumab in Stage II-III ER+ HER2+ Breast Cancer (PALTAN) | Terminated | USA | 0 |
NCT02924883 | Phase II | Trastuzumab Atezolizumab + Trastuzumab | A Study to Evaluate the Efficacy and Safety of Trastuzumab Emtansine in Combination With Atezolizumab or Atezolizumab-Placebo in Participants With Human Epidermal Growth Factor-2 (HER2) Positive Locally Advanced or Metastatic Breast Cancer (BC) Who Received Prior Trastuzumab and Taxane Based Therapy (KATE2) | Completed | USA | ITA | GBR | ESP | DEU | CAN | AUS | 2 |
NCT02947685 | Phase III | Fulvestrant Pertuzumab Letrozole Anastrozole Exemestane Palbociclib Trastuzumab | Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer (PATINA) | Active, not recruiting | USA | NZL | ITA | FRA | ESP | DEU | AUS | 1 |
NCT03054363 | Phase Ib/II | Letrozole + Palbociclib + Tucatinib | Tucatinib, Palbociclib and Letrozole in Metastatic Hormone Receptor Positive and HER2-positive Breast Cancer | Completed | USA | 0 |
NCT03112590 | Phase Ib/II | Interferon gamma + Paclitaxel + Pertuzumab + Trastuzumab | Phase I-II Study of Interferon-gamma in Patients With HER-2 Positive Breast Cancer | Completed | USA | 0 |
NCT03125928 | Phase II | Atezolizumab + Paclitaxel + Pertuzumab + Trastuzumab | Clinical Trial of Atezolizumab With Paclitaxel, Trastuzumab, and Pertuzumab in Patients With Metastatic HER-2 Positive Breast Cancer | Active, not recruiting | USA | 0 |
NCT03135171 | Phase I | Pertuzumab + Tocilizumab + Trastuzumab | Trastuzumab and Pertuzumab in Combination With Tocilizumab in Subjects With Metastatic HER2 Positive Breast Cancer Resistant to Trastuzumab | Completed | USA | 0 |
NCT03179904 | Phase II | Paclitaxel + Trastuzumab + TVB-2640 Anastrozole + Trastuzumab + TVB-2640 Fulvestrant + Trastuzumab + TVB-2640 Exemestane + Trastuzumab + TVB-2640 | TVB-2640 and Trastuzumab With Paclitaxel or Endocrine Therapy for Treatment of HER2 Positive Metastatic Breast Cancer | Active, not recruiting | USA | 0 |
NCT03190967 | Phase Ib/II | Ado-trastuzumab emtansine Ado-trastuzumab emtansine + Temozolomide | T-DM1 Alone Versus T-DM1 and Metronomic Temozolomide in Secondary Prevention of HER2-Positive Breast Cancer Brain Metastases Following Stereotactic Radiosurgery | Terminated | USA | 0 |
NCT03284723 | Phase I | Letrozole + Palbociclib + PF-06804103 PF-06804103 | PF-06804103 Dose Escalation in HER2 Positive and Negative (Negative Only in Part 2) Solid Tumors | Terminated | USA | ITA | ESP | AUS | 2 |
NCT03304080 | Phase Ib/II | Anastrozole + Palbociclib + Pertuzumab + Trastuzumab | Anastrozole, Palbociclib, Trastuzumab and Pertuzumab in HR-positive, HER2-positive Metastatic Breast | Active, not recruiting | USA | 0 |
NCT03319459 | Phase I | FATE-NK100 FATE-NK100 + Trastuzumab Cetuximab + FATE-NK100 | FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors | Completed | USA | 0 |
NCT03321981 | Phase II | Letrozole + Zenocutuzumab Anastrozole + Zenocutuzumab Fulvestrant + Zenocutuzumab Exemestane + Zenocutuzumab Trastuzumab + Zenocutuzumab Trastuzumab + Vinorelbine + Zenocutuzumab | MCLA-128 With Trastuzumab/Chemotherapy in HER2+ and With Endocrine Therapy in ER+ and Low HER2 Breast Cancer | Completed | USA | NLD | GBR | FRA | ESP | BEL | 1 |
NCT03324425 | Phase II | Simvastatin | Simvastatin Plus Dual Anti-HER2 Therapy for Metastatic Breast Cancer (SIMPHONY) | Active, not recruiting | USA | 0 |
NCT03329378 | Phase II | Docetaxel + Paclitaxel + Pegfilgrastim + Pertuzumab + Trastuzumab Cyclophosphamide + Doxorubicin + Paclitaxel + Pertuzumab + Trastuzumab | Neoadjuvant Dose-Dense For Early Her2Neu Positive Breast Cancer | Terminated | USA | 0 |
NCT03330561 | Phase I | PRS-343 | PRS-343 in HER2-Positive Solid Tumors | Completed | USA | 0 |
NCT03364348 | Phase I | Trastuzumab + Utomilumab Ado-trastuzumab emtansine + Utomilumab | 4-1BB Agonist Monoclonal Antibody PF-05082566 With Trastuzumab Emtansine or Trastuzumab in Treating Patients With Advanced HER2-Positive Breast Cancer | Completed | USA | 0 |
NCT03368729 | Phase Ib/II | Niraparib + Trastuzumab | Niraparib in Combination With Trastuzumab in Metastatic HER2+ Breast Cancer | Recruiting | USA | 0 |
NCT03377387 | Phase Ib/II | Capecitabine + Neratinib | Capecitabine 7/7 Schedule With Neratinib in Patients With Metastatic HER2-Positive Breast Cancer | Active, not recruiting | USA | 0 |
NCT03379428 | Phase Ib/II | Trastuzumab Ibrutinib + Trastuzumab | Trial of Ibrutinib Plus Trastuzumab in HER2-amplified Metastatic Breast Cancer | Active, not recruiting | USA | 0 |
NCT03384914 | Phase II | HER2-pulsed DC1 vaccine pUMVC3-IGFBP2-HER2-IGF1R vaccine | Vaccine to Prevent Recurrence in Patients With HER-2 Positive Breast Cancer | Active, not recruiting | USA | 0 |
NCT03387553 | Phase I | HER2-pulsed DC1 vaccine | HER2 Directed Dendritic Cell Vaccine During Neoadjuvant Therapy of HER2+Breast Cancer | Active, not recruiting | USA | 0 |
NCT03414658 | Phase II | Avelumab + Trastuzumab + Utomilumab + Vinorelbine Avelumab + Trastuzumab + Vinorelbine Avelumab + Trastuzumab + Utomilumab Trastuzumab + Vinorelbine | The AVIATOR Study: Trastuzumab and Vinorelbine With Avelumab OR Avelumab & Utomilumab in Advanced HER2+ Breast Cancer | Active, not recruiting | USA | 0 |
NCT03417544 | Phase II | Atezolizumab + Pertuzumab + Trastuzumab | Atezolizumab + Pertuzumab + Trastuzumab In CNS Mets In BC | Active, not recruiting | USA | 0 |
NCT03429101 | Phase I | Ado-trastuzumab emtansine + Poziotinib | A Study of Poziotinib in Combination With T-DM1 in HER2-Positive Breast Cancer | Terminated | USA | 0 |
NCT03433313 | Phase III | Cyclophosphamide + Epirubicin + Paclitaxel + Trastuzumab Cyclophosphamide + EG12014 + Epirubicin + Paclitaxel | Efficacy and Safety Study of EG12014 Compared With Herceptin in Subjects With HER2 Positive Early Breast Cancer | Completed | USA | 10 |
NCT03451162 | Phase I | DHES0815A | Safety, Tolerability, and Pharmacokinetic (PK) Study of DHES0815A in Participants With Human Epidermal Growth Factor Receptor (HER)2-Positive Breast Cancer | Completed | USA | 1 |
NCT03493854 | Phase III | Pertuzumab + Trastuzumab Cyclophosphamide + Doxorubicin + Paclitaxel + Pertuzumab + Trastuzumab | A Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Participants With HER2-Positive Early Breast Cancer (FeDeriCa) | Completed | USA | POL | ITA | GBR | FRA | ESP | DEU | CZE | CAN | BRA | BEL | ARG | 7 |
NCT03501979 | Phase II | Capecitabine + Trastuzumab + Tucatinib | Tucatinib, Trastuzumab, and Capecitabine for the Treatment of HER2+ LMD | Active, not recruiting | USA | 0 |
NCT03521245 | Phase I | Trastuzumab | Molecular Pathway Activation Markers Predicting Efficacy of Trastuzumab Therapy for HER2-positive Breast Cancer | Unknown status | USA | 1 |
NCT03523585 | Phase III | Trastuzumab deruxtecan Capecitabine + Lapatinib Capecitabine + Trastuzumab | DS-8201a in Pre-treated HER2 Breast Cancer That Cannot be Surgically Removed or Has Spread [DESTINY-Breast02] | Active, not recruiting | USA | TUR | ITA | ISR | GRC | GBR | FRA | ESP | DEU | CZE | BRA | BEL | AUS | 2 |
NCT03529110 | Phase III | Trastuzumab deruxtecan Ado-trastuzumab emtansine | DS-8201a Versus T-DM1 for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive, Unresectable and/or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane [DESTINY-Breast03] | Active, not recruiting | USA | ITA | GBR | FRA | ESP | DEU | CAN | BRA | BEL | AUS | 5 |
NCT03530696 | Phase II | Ado-trastuzumab emtansine Ado-trastuzumab emtansine + Palbociclib | T-DM1 and Palbociclib for Metastatic HER2 Breast Cancer (T-DM1) | Completed | USA | 0 |
NCT03564782 | Phase I | PVSRIPO | Examining Bioactivity of PVSRIPO in Invasive Breast Cancer | Completed | USA | 0 |
NCT03571633 | Phase II | Paclitaxel + Pegfilgrastim + Trastuzumab Paclitaxel + Trastuzumab | Impact of Pegfilgrastim on Trastuzumab Anti-tumor Effect and ADCC in Operable HER2+ Breast Cancer Breast Cancer (BREASTIMMU02) | Recruiting | FRA | 0 |
NCT03587740 | Phase II | Ado-trastuzumab emtansine | ATOP TRIAL: T-DM1 in HER2 Positive Breast Cancer | Active, not recruiting | USA | 0 |
NCT03595592 | Phase III | Carboplatin + Paclitaxel + Pertuzumab + Trastuzumab Atezolizumab + Carboplatin + Paclitaxel + Pertuzumab + Trastuzumab Atezolizumab + Carboplatin + Cyclophosphamide + Doxorubicin + Paclitaxel + Pertuzumab + Trastuzumab | Neoadjuvant Treatment of HER2 Positive Early High-risk and Locally Advanced Breast Cancer (APTneo) | Active, not recruiting | ITA | ESP | DEU | AUT | 0 |
NCT03620201 | Phase I | Bintrafusp alfa | M7824 in Treating Patients With Stage II-III HER2 Positive Breast Cancer | Completed | USA | 0 |
NCT03630809 | Phase II | HER2-pulsed DC1 vaccine | Immune Response and Potential Booster for Patients Who Have Received HER2-pulsed DC1 | Terminated | USA | 0 |
NCT03644186 | Phase II | Letrozole + Palbociclib + Pertuzumab + Trastuzumab Paclitaxel + Pertuzumab + Trastuzumab | To Reduce the Use of Chemotherapy in Postmenopausal Patients With ER-positive and HER2-positive Breast Cancer (TOUCH) (TOUCH) | Completed | ITA | FRA | CHE | BEL | 0 |
NCT03674112 | Phase II | Pertuzumab + Trastuzumab | A Study to Evaluate Patient Preference and Satisfaction of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Participants With HER2-Positive Early Breast Cancer | Completed | USA | SWE | LBN | FIN | ESP | BRA | ARG | 10 |
NCT03709082 | Phase Ib/II | Ado-trastuzumab emtansine + Letrozole + Palbociclib | Palbociclib in Estrogen Receptor Positive (ER+) Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer | Terminated | USA | 0 |
NCT03716180 | Phase I | Paclitaxel + Pertuzumab + Trastuzumab | DAPHNe: Paclitaxel/Trastuzumab/Pertuzumab in HER2-Positive BC | Active, not recruiting | USA | 0 |
NCT03726879 | Phase III | Cyclophosphamide + Doxorubicin Atezolizumab + Cyclophosphamide + Doxorubicin Atezolizumab + Paclitaxel + Pertuzumab + Trastuzumab Atezolizumab + Pertuzumab + Trastuzumab Pertuzumab + Trastuzumab Paclitaxel + Pertuzumab + Trastuzumab | A Study To Evaluate the Efficacy and Safety Of Atezolizumab or Placebo in Combination With Neoadjuvant Doxorubicin + Cyclophosphamide Followed By Paclitaxel + Trastuzumab + Pertuzumab In Early Her2-Positive Breast Cancer (IMpassion050) | Completed | USA | POL | ITA | ESP | DEU | CZE | CAN | BRA | 4 |
NCT03747120 | Phase II | Paclitaxel + Pembrolizumab + Pertuzumab + Trastuzumab Paclitaxel + Pembrolizumab + Trastuzumab Paclitaxel + Pertuzumab + Trastuzumab | Neoadjuvant Her2-targeted Therapy and Immunotherapy With Pembrolizumab | Active, not recruiting | USA | 0 |
NCT03765983 | Phase II | GDC-0084 + Trastuzumab | GDC-0084 in Combination With Trastuzumab for Patients With HER2-Positive Breast Cancer Brain Metastases | Active, not recruiting | USA | 0 |
NCT03846583 | Phase I | Abemaciclib + Trastuzumab + Tucatinib | Tucatinib + Abemaciclib + Herceptin for HER2+ MBC | Withdrawn | 0 | |
NCT03931551 | Phase II | Olaparib + Trastuzumab | Olaparib+Trastuzumab in HER2[+],Breast Cancer Susceptibility Gene (BRCA) Mutated Advanced Breast Cancer (OPHELIA) | Terminated | ESP | 0 |
NCT03975647 | Phase III | Ado-trastuzumab emtansine + Tucatinib Ado-trastuzumab emtansine | A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer | Active, not recruiting | USA | SWE | NLD | ITA | ISR | GBR | FRA | ESP | DNK | DEU | CHE | CAN | BEL | AUT | AUS | 5 |
NCT03983395 | Phase Ib/II | GBR1302 | Study of GBR 1302 (CD3 Bispecific Ab) in HER2-positive Metastatic Breast Cancer | Terminated | USA | 0 |
NCT03988036 | Phase II | Pembrolizumab + Pertuzumab + Trastuzumab | A Study With Pembrolizumab in Combination With Dual Anti-HER2 Blockade With Trastuzumab and Pertuzumab in Early Breast Cancer Patients With Molecular HER2-enriched Intrinsic Subtype (Keyriched-1) | Completed | DEU | 0 |
NCT04042701 | Phase I | Pembrolizumab + Trastuzumab deruxtecan | DS8201a and Pembrolizumab in Participants With Locally Advanced/Metastatic Breast or Non-Small Cell Lung Cancer | Recruiting | USA | GBR | FRA | ESP | 0 |
NCT04054752 | Phase I | NT-I7 | Vaccine Response With NT-I7 | Withdrawn | USA | 0 |
NCT04092673 | Phase Ib/II | Fulvestrant + Zotatifin Zotatifin Sotorasib + Zotatifin Abemaciclib + Fulvestrant + Zotatifin Trastuzumab + Zotatifin | Study of eFT226 in Subjects With Selected Advanced Solid Tumor Malignancies (Zotatifin) | Recruiting | USA | 0 |
NCT04102618 | Phase I | Atezolizumab + Pelareorep Atezolizumab + Pelareorep + Trastuzumab Letrozole + Pelareorep Atezolizumab + Letrozole + Pelareorep | A Window-of-opportunity Study of Pelareorep in Early Breast Cancer (AWARE-1) | Terminated | ESP | 0 |
NCT04108858 | Phase Ib/II | Copanlisib + Pertuzumab + Trastuzumab Pertuzumab + Trastuzumab | Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Maintenance Treatment (Trastuzumab and Pertuzumab) After Initial Chemotherapy in a Phase Ib/II Trial for Advanced HER2 Positive Breast Cancer | Terminated | USA | 0 |
NCT04120246 | Phase I | alpha-TEA + Trastuzumab | Alpha-TEA and Trastuzumab for the Treatment of Refractory HER2+ Metastatic Breast Cancer | Suspended | USA | 0 |
NCT04147819 | Phase I | BAY2701439 | A First in Human Study of BAY2701439 to Look at Safety, How the Body Absorbs, Distributes and Excretes the Drug, and How Well the Drug Works in Participants With Advanced Cancer Expressing the HER2 Protein | Completed | USA | GBR | 0 |
NCT04188548 | Phase I | Abemaciclib + LY3484356 LY3484356 Abemaciclib + LY3484356 + Trastuzumab Abemaciclib + Anastrozole + LY3484356 Abemaciclib + Exemestane + LY3484356 Alpelisib + LY3484356 Everolimus + LY3484356 Abemaciclib + Letrozole + LY3484356 | A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial Cancer (EMBER) | Active, not recruiting | USA | FRA | ESP | BEL | AUS | 3 |
NCT04208178 | Phase III | Pertuzumab + Trastuzumab Alpelisib + Pertuzumab + Trastuzumab | Study of Alpelisib (BYL719) in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy in Patients With HER2-positive Advanced Breast Cancer With a PIK3CA Mutation (EPIK-B2) | Active, not recruiting | USA | ITA | FRA | ESP | BEL | 2 |
NCT04224272 | Phase II | Fulvestrant + Palbociclib + ZW25 | A Study of ZW25 (Zanidatamab) With Palbociclib Plus Fulvestrant in Patients With HER2+/HR+ Advanced Breast Cancer | Active, not recruiting | USA | ESP | CAN | 0 |
NCT04246671 | Phase Ib/II | TAEK-VAC-HerBy Pertuzumab + TAEK-VAC-HerBy + Trastuzumab Ado-trastuzumab emtansine + TAEK-VAC-HerBy TAEK-VAC-HerBy + Trastuzumab | TAEK-VAC-HerBy Vaccine for Brachyury and HER2 Expressing Cancer | Active, not recruiting | USA | 0 |
NCT04253561 | Phase I | Ipatasertib + Pertuzumab + Trastuzumab | Ipatasertib + Pertuzumab +Trastuzumab in Advanced HER2+ PI3KCA-mutant Breast Cancer Patients (IPATHER) | Recruiting | ESP | 0 |
NCT04266249 | Phase II | Pertuzumab + Trastuzumab Paclitaxel + Pertuzumab + Trastuzumab Ado-trastuzumab emtansine Docetaxel + Pertuzumab + Trastuzumab Nab-paclitaxel + Pertuzumab + Trastuzumab | CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy | Recruiting | USA | 1 |
NCT04296942 | Phase I | Bintrafusp alfa + FPV-Brachyury + MVA-BN-Brachyury Ado-trastuzumab emtansine + Bintrafusp alfa + Entinostat + FPV-Brachyury + MVA-BN-Brachyury Ado-trastuzumab emtansine + Bintrafusp alfa + FPV-Brachyury + MVA-BN-Brachyury | BN-Brachyury, Entinostat, Adotrastuzumab Emtansine and M7824 in Advanced Stage Breast Cancer (BrEAsT) | Terminated | USA | 0 |
NCT04298918 | Phase Ib/II | Ado-trastuzumab emtansine + Venetoclax Ado-trastuzumab emtansine | A Study Evaluating the Safety and Efficacy of Venetoclax in Combination With Trastuzumab Emtansine in Patients With Previously Treated HER2-Positive Locally Advanced or Metastatic Breast Cancer | Terminated | AUS | 1 |
NCT04301375 | Phase II | Paclitaxel + Pertuzumab + Trastuzumab Ado-trastuzumab emtansine | Omission of Surgery and Sentinel Lymph Node Dissection in Clinically Low-risk HER2positive Breast Cancer With High HER2 Addiction and a Complete Response Following Standard Anti- HER2-based Neoadjuvant Therapy (ELPIS Trial) (ELPIS) | Not yet recruiting | ESP | 0 |
NCT04348747 | Phase II | Anti-HER2/HER3 DC vaccine + Celecoxib + Interferon alpha-2b + Pembrolizumab + Rintatolimod Anti-HER2/HER3 DC vaccine + Celecoxib + Interferon alpha-2b + Rintatolimod | Dendritic Cell Vaccines Against Her2/Her3, Cytokine Modulation Regimen, and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer | Recruiting | USA | 0 |
NCT04351230 | Phase II | Abemaciclib + Ado-trastuzumab emtansine Ado-trastuzumab emtansine | Abemaciclib With or Without T-DM1 for the Treatment of HER2-Positive Metastatic Breast Cancer | Withdrawn | USA | 0 |
NCT04395508 | Expanded access | Pertuzumab + Trastuzumab | An Expanded Access Study to Provide at Home Subcutaneous Administration of Pertuzumab and Trastuzumab Fixed-Dose Combination (PH FDC SC) for Patients With HER2-Positive Breast Cancer During the COVID-19 Pandemic | Approved for marketing | USA | 0 |
NCT04420598 | Phase II | Trastuzumab deruxtecan | DS-8201a for trEatment of aBc, BRain Mets, And Her2[+] Disease (DEBBRAH) | Completed | ESP | 1 |
NCT04450732 | Phase I | GQ1001 | Safety of GQ1001 in Adult Patients With HER2-Positive Advanced Solid Tumors | Recruiting | USA | AUS | 1 |
NCT04457596 | Phase III | Ado-trastuzumab emtansine Ado-trastuzumab emtansine + Tucatinib | T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial | Recruiting | USA | CAN | 1 |
NCT04467515 | Phase Ib/II | CAM-H2 | A Study to Evaluate Safety, Tolerability, Dosimetry, and Preliminary Efficacy of the HER2 Directed Radioligand CAM-H2 in Patients With Advanced/Metastatic HER2-Positive Breast, Gastric, and Gastro-Esophageal Junction (GEJ) Cancer | Terminated | USA | CAN | 0 |
NCT04509596 | Phase I | DZD1516 + Trastuzumab Capecitabine + DZD1516 Ado-trastuzumab emtansine + DZD1516 Capecitabine + DZD1516 + Trastuzumab DZD1516 | DZD1516 in Combination With Trastuzumab and Capecitabine, or in Combination With T-DM1, in Patients With Metastatic HER2 Positive Breast Cancer | Active, not recruiting | USA | 1 |
NCT04512261 | Phase Ib/II | Pembrolizumab + Trastuzumab + Tucatinib | TOPAZ: Tucatinib in COmbination With Pembrolizumab And TrastuZumab in Patients With HER2-Positive Breast Cancer Brain Metastases | Withdrawn | USA | 0 |
NCT04538742 | Phase Ib/II | Durvalumab + Trastuzumab deruxtecan Pertuzumab + Trastuzumab deruxtecan Durvalumab + Paclitaxel + Trastuzumab deruxtecan Paclitaxel + Trastuzumab deruxtecan Trastuzumab deruxtecan | A Phase 1b/2 Study of T-DXd Combinations in HER2-positive Metastatic Breast Cancer (DB-07) | Active, not recruiting | USA | TUR | POL | ITA | GBR | FRA | ESP | DEU | CAN | BRA | AUS | 4 |
NCT04539938 | Phase II | Trastuzumab deruxtecan + Tucatinib | A Study of Tucatinib Plus Trastuzumab Deruxtecan in HER2+ Breast Cancer (HER2CLIMB-04) | Active, not recruiting | USA | 0 |
NCT04578106 | Phase II | Pertuzumab + Trastuzumab | Omission of Surgery in Clinically Low-risk HER2positive Breast Cancer With High HER2 Addiction and a Complete Response Following Standard Anti-HER2-based Neoadjuvant Therapy (ELPIS) | Recruiting | ESP | 0 |
NCT04602117 | Phase I | Paclitaxel + Trastuzumab Duocarmazine | Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer | Withdrawn | USA | 0 |
NCT04622319 | Phase III | Trastuzumab deruxtecan Ado-trastuzumab emtansine | A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05) | Active, not recruiting | USA | TUR | ROU | POL | NLD | ITA | ISR | IRL | GRC | GBR | FRA | ESP | DNK | DEU | CZE | CAN | BRA | BEL | AUS | ARG | 11 |
NCT04675827 | Phase II | Ado-trastuzumab emtansine Pertuzumab/trastuzumab/hyaluronidase-zzxf | De-escalation Adjuvant Chemo in HER2+/ER-/Node-neg Early BC Patients Who Achieved pCR After Neoadjuvant Chemo & Dual HER2 Blockade (Decrescendo) | Suspended | ISR | FRA | CHE | BEL | AUS | 1 |
NCT04680442 | Phase II | Trastuzumab Ado-trastuzumab emtansine Pertuzumab | Safety of Continuing HER-2 Directed Therapy in Overt Left Ventricular Dysfunction (SCHOLAR-2) | Recruiting | CAN | BRA | 1 |
NCT04733118 | Phase II | Ado-trastuzumab emtansine Pertuzumab + Trastuzumab | Chemotherapy-Free pCR-Guided Strategy With Trastuzumab-pertuzumab and T-DM1 in HER2-positive Early Breast Cancer (PHERGAIN-2) | Active, not recruiting | ITA | HUN | ESP | DEU | BGR | 0 |
NCT04739761 | Phase III | Trastuzumab deruxtecan | A Study of T-DXd in Participants With or Without Brain Metastasis Who Have Previously Treated Advanced or Metastatic HER2 Positive Breast Cancer (DESTINY-B12) | Active, not recruiting | USA | SWE | POL | NOR | NLD | ITA | IRL | GBR | FIN | ESP | DNK | DEU | CHE | CAN | BEL | AUS | 2 |
NCT04740918 | Phase III | Ado-trastuzumab emtansine + Atezolizumab Ado-trastuzumab emtansine | A Study of Trastuzumab Emtansine in Combination With Atezolizumab or Placebo as a Treatment for Participants With Human Epidermal Growth Factor 2 (HER2)-Positive and Programmed Death-ligand 1 (PD-L1)-Positive Locally Advanced (LABC) or Metastatic Breast Cancer (MBC) (KATE3) | Terminated | USA | TUR | SVN | POL | NOR | ITA | HRV | GRC | GBR | FRA | FIN | ESP | CAN | BRA | AUS | 6 |
NCT04752059 | Phase II | Trastuzumab deruxtecan | Phase II Study of T-DX in HER2-positive Breast Cancer Brain Metastases (TUXEDO-1) | Completed | AUT | 0 |
NCT04752332 | Phase III | Abemaciclib | A Study of Abemaciclib (LY2835219) Plus Hormone Therapy in Participants With Early Breast Cancer (eMonarcHER) | Terminated | USA | ITA | ISR | HUN | GRC | GBR | FRA | ESP | DEU | CHE | BRA | BEL | AUT | AUS | ARG | 5 |
NCT04784715 | Phase III | Pertuzumab + Trastuzumab deruxtecan Docetaxel + Pertuzumab + Trastuzumab Paclitaxel + Pertuzumab + Trastuzumab Trastuzumab deruxtecan | Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09) | Active, not recruiting | USA | TUR | SWE | ROU | ITA | ISR | HUN | GBR | FRA | ESP | DNK | DEU | CAN | BRA | BEL | ARG | 11 |
NCT04789096 | Phase II | Pembrolizumab + Trastuzumab + Tucatinib Capecitabine + Pembrolizumab + Trastuzumab + Tucatinib | Tucatinib Together With Pembrolizumab and Trastuzumab (TUGETHER) | Recruiting | AUS | 0 |
NCT04834778 | Phase I | HC-5404-FU | A Study of HC-5404-FU to Establish the Maximum Tolerated Dose (MTD) | Completed | USA | 0 |
NCT04873362 | Phase III | Ado-trastuzumab emtansine Trastuzumab Atezolizumab + Trastuzumab Ado-trastuzumab emtansine + Atezolizumab | A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy (Astefania) | Recruiting | USA | TUR | ROU | POL | NZL | ITA | HUN | GRC | GBR | FRA | ESP | DNK | DEU | CZE | BRA | BGR | BEL | AUT | AUS | ARG | 16 |
NCT04886531 | Phase II | Anastrozole + Neratinib + Trastuzumab Letrozole + Neratinib + Trastuzumab Neratinib Anastrozole + Neratinib Letrozole + Neratinib Letrozole Anastrozole Anastrozole + Trastuzumab | Trial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in ER-Positive, HER-2 Positive Breast Cancers | Recruiting | USA | 0 |
NCT04893109 | Phase II | Paclitaxel + Trastuzumab Ado-trastuzumab emtansine + Trastuzumab | ATEMPT 2.0: Adjuvant T-DM1 vs TH | Recruiting | USA | 0 |
NCT04896320 | Phase Ib/II | Trastuzumab + Tucatinib + Vinorelbine Capecitabine + Trastuzumab + Tucatinib | Tucatinib With Chemotherapy and Trastuzumab in Advanced Her-2-neu Overexpressing, Previously Treated Breast Cancer. (2019-101826) | Withdrawn | USA | 0 |
NCT04928261 | FDA approved | Trastuzumab | Evaluating 6-months of HER2-targeted Therapy in Patients With HER2 Positive Early-stage Breast Cancer That Achieve a Pathological Complete Response to Neoadjuvant Systemic Therapy | Recruiting | CAN | 0 |
NCT04982926 | Phase I | TAS2940 | A Study of TAS2940 in Participants With Locally Advanced or Metastatic Solid Tumor Cancer | Active, not recruiting | USA | FRA | 0 |
NCT04993014 | Phase II | Trastuzumab Pertuzumab + Trastuzumab | Circulating Tumor Cells and Treatment De-escalation After Neoadjuvant Therapy for HER2 Positive Breast Cancer (HER2Cell) | Recruiting | BRA | 0 |
NCT05020860 | Phase II | Cyclophosphamide + Doxorubicin + Paclitaxel Carboplatin + Cyclophosphamide + Doxorubicin + Paclitaxel Carboplatin + Cyclophosphamide + Doxorubicin + Paclitaxel + Pembrolizumab Cyclophosphamide + Doxorubicin + Paclitaxel + Pertuzumab + Trastuzumab | Correlation of Clinical Response to Pathologic Response in Patients With Early Breast Cancer (RESPONSE) | Recruiting | USA | 0 |
NCT05027139 | Phase Ib/II | Evorpacept + ZW25 | A Study of Zanidatamab (ZW25) With Evorpacept (ALX148) in Patients With Advanced HER2-expressing Cancer | Active, not recruiting | USA | 0 |
NCT05035836 | Phase II | Letrozole + ZW25 ZW25 Tamoxifen + ZW25 | A Phase 2 Single-Arm Open-Label Pilot Trial Evaluating Zanidatamab (ZW25) in Patients With Early Stage HER2/Neu Positive (HER2+) Breast Cancer (BC) | Active, not recruiting | USA | 0 |
NCT05036005 | FDA approved | Pertuzumab + Trastuzumab Trastuzumab | Neoadjuvant Ontruzant (SB3) in Patients With HER2-positive Early Breast Cancer: An Open-Label (NeoON) (NeoON) | Recruiting | DEU | 0 |
NCT05041842 | Phase II | Anastrozole + Pertuzumab + Trastuzumab + Tucatinib Fulvestrant + Pertuzumab + Trastuzumab + Tucatinib Letrozole + Pertuzumab + Trastuzumab + Tucatinib | Treatment With Tucatinib in Patients With an Isolated Brain Progression of a Metastatic Breast Cancer (InTTercePT) | Active, not recruiting | FRA | 0 |
NCT05063786 | Phase III | Alpelisib + Fulvestrant + Trastuzumab Trastuzumab + Vinorelbine Alpelisib + Trastuzumab Capecitabine + Trastuzumab Eribulin + Trastuzumab | Trastuzumab + Alpelisib +/- Fulvestrant vs Trastuzumab + CT in Patients With PIK3CA Mutated Previously Treated HER2+ Advanced BrEasT Cancer (ALPHABET) (ALPHABET) | Active, not recruiting | NLD | ITA | FRA | ESP | CHE | AUT | 0 |
NCT05069935 | Phase I | Atezolizumab + FT538 Cetuximab + FT538 FT538 + Trastuzumab FT538 + Pembrolizumab FT538 + Nivolumab Avelumab + FT538 Cyclophosphamide + Fludarabine | FT538 in Combination With Monoclonal Antibodies in Advanced Solid Tumors | Terminated | USA | 0 |
NCT05113251 | Phase III | Paclitaxel + Pertuzumab + Trastuzumab + Trastuzumab deruxtecan Trastuzumab deruxtecan Cyclophosphamide + Doxorubicin + Paclitaxel + Pertuzumab + Trastuzumab | Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast Cancer | Active, not recruiting | USA | POL | ITA | ESP | DEU | CAN | BRA | BGR | 10 |
NCT05132582 | Phase III | Pertuzumab + Trastuzumab Pertuzumab + Trastuzumab + Tucatinib | A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer (HER2CLIMB-05) | Active, not recruiting | USA | POL | NLD | ITA | GRC | GBR | FRA | FIN | ESP | DEU | CZE | CHE | CAN | BRA | BEL | AUT | AUS | 6 |
NCT05163223 | Phase II | AST-301 + Capecitabine + Pembrolizumab + Sargramostim Capecitabine + Pembrolizumab + Sargramostim | Therapeutic Cancer Vaccine (AST-301, pNGVL3-hICD) in Patients With Breast Cancer (Cornerstone001) | Terminated | USA | 1 |
NCT05180006 | Phase II | Atezolizumab Atezolizumab + Pertuzumab + Trastuzumab Atezolizumab + Ipatasertib Atezolizumab + Bevacizumab | Impact of Neoadjuvant Immunotherapy in Early Stage Breast Cancer Before Standard Therapy (BIS-Program) | Recruiting | FRA | 0 |
NCT05230810 | Phase Ib/II | Alpelisib + Fulvestrant + Tucatinib | Clinical Trial of Alpelisb and Tucatinib in Patients With PIK3CA-Mutant HER2+ Metastatic Breast Cancer. | Recruiting | USA | 0 |
NCT05232916 | Phase III | GLSI-100 | Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects (FLAMINGO-01) | Recruiting | USA | POL | ITA | FRA | ESP | DEU | 0 |
NCT05262400 | Phase II | Letrozole + PF-07104091 + PF-07220060 Fulvestrant + PF-07104091 + PF-07220060 PF-07104091 + PF-07220060 | A Study to Learn About the Study Medicine (Called PF-07220060 in Combination With PF-07104091) In Participants With Breast Cancer and Solid Tumors | Active, not recruiting | USA | ESP | CZE | BRA | BGR | ARG | 3 |
NCT05296798 | Phase III | Giredestrant + Pertuzumab/trastuzumab/hyaluronidase-zzxf Docetaxel + Paclitaxel + Pertuzumab/trastuzumab/hyaluronidase-zzxf | A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer) | Recruiting | USA | TUR | POL | LBN | ITA | HUN | GBR | FRA | ESP | DEU | BRA | BEL | ARG | 17 |
NCT05306041 | Phase II | Inavolisib + Pertuzumab/trastuzumab/hyaluronidase-zzxf + Tamoxifen Pertuzumab/trastuzumab/hyaluronidase-zzxf + Tamoxifen | Neoadjuvant Endocrine Therapy +/- the PI3K Inhibitor Inavolisib in HER2+, HR+, PIK3CA Mutant Early Breast Cancer (GeparPiPPa) | Recruiting | DEU | 0 |
NCT05319873 | Phase Ib/II | Carboplatin + Docetaxel + Pertuzumab + Trastuzumab Ribociclib + Trastuzumab + Tucatinib Fulvestrant + Ribociclib + Trastuzumab + Tucatinib | Ribociclib, Tucatinib, and Trastuzumab for the Treatment of HER2 Positive Breast Cancer | Recruiting | USA | 0 |
NCT05323955 | Phase II | Pertuzumab + Tucatinib Trastuzumab + Tucatinib Ado-trastuzumab emtansine + Tucatinib | Secondary BRain Metastases Prevention After Isolated Intracranial Progression on Trastuzumab/Pertuzumab or T-DM1 in Patients With aDvanced Human Epidermal Growth Factor Receptor 2+ brEast Cancer With the Addition of Tucatinib (BRIDGET) | Recruiting | USA | 0 |
NCT05325632 | Phase II | HER2-pulsed DC1 vaccine + Paclitaxel + Pertuzumab + Trastuzumab | Study of HER2 Directed Dendritic Cell (DC1) Vaccine + Weekly Paclitaxel, Trastuzumab & Pertuzumab | Recruiting | USA | 0 |
NCT05332561 | Phase II | Olaparib Ipatasertib Sacituzumab govitecan-hziy Inavolisib Pertuzumab/trastuzumab/hyaluronidase-zzxf Atezolizumab | Genomics Guided Targeted Post-neoadjuvant Therapy in Patients With Early Breast Cancer (COGNITION-GUIDE) | Recruiting | DEU | 0 |
NCT05376878 | FDA approved | Trastuzumab Trastuzumab deruxtecan | An Investigational Scan (64Cu-DOTA-Trastuzumab PET/MRI) in Imaging Patients With HER2+ Breast Cancer With Brain Metastasis | Recruiting | USA | 0 |
NCT05378464 | Phase I | Pepinemab + Trastuzumab HER2-pulsed DC1 vaccine | Adoptive T Cell Therapy Following HER2-Pulsed Dendritic Cell Vaccine & Pepinemab /Trastuzumab in Patients w/ Metastatic HER2+ Breast Cancer | Recruiting | USA | 0 |
NCT05385705 | Phase I | Aldesleukin + Cyclophosphamide + Pertuzumab + Trastuzumab | A Study of Allogenic Natural Killer Cells in Combination With Trastuzumab and Pertuzumab in Adult Patients With Refractory Metastatic Her2 Positive Breast Cancer. NK-ACT-BC_2020 | Recruiting | ESP | 0 |
NCT05388149 | Phase II | Neratinib | Kadcyla And Neratinib for Interception of HER2+ Breast Cancer With Molecular Residual Disease | Recruiting | CAN | 0 |
NCT05458674 | Phase II | Eribulin + Trastuzumab + Tucatinib | Tucatinib+Trastuzumab+Eribulin in HER2+ MBC | Recruiting | USA | 0 |
NCT05511844 | Phase I | ORM-5029 | Study of ORM-5029 in Subjects With HER2-Expressing Advanced Solid Tumors | Recruiting | USA | 0 |
NCT05553522 | Phase I | Capecitabine + Trastuzumab + Tucatinib | Tucatinib, Trastuzumab, and Capecitabine With SRS for Brain Metastases From HER-2 Positive Breast Cancer | Recruiting | USA | 0 |
NCT05555251 | Phase Ib/II | BI-1607 + Trastuzumab | BI-1607 in Combination With Trastuzumab in Subjects With HER2-positive Advanced Solid Tumors (CONTRAST) | Active, not recruiting | GBR | ESP | DEU | 0 |
NCT05583110 | Phase II | Trastuzumab + Tucatinib + Vinorelbine | Efficacy and Safety of the Combination of Trastuzumab Plus TUCAtinib Plus viNorelbine in Patients With HER2-positive Non-resectable Locally Advanced or Metastatic Breast Cancer (TrasTUCAN) | Recruiting | ESP | 0 |
NCT05593094 | Phase I | ZN-A-1041 Ado-trastuzumab emtansine + ZN-A-1041 Trastuzumab deruxtecan + ZN-A-1041 Pertuzumab/trastuzumab/hyaluronidase-zzxf + ZN-A-1041 Pertuzumab + Trastuzumab + ZN-A-1041 | A Phase 1 Trial of ZN-A-1041 Enteric Capsules or Combination in Patients With HER2-Positive Advanced Solid Tumors | Recruiting | USA | NZL | GBR | FRA | ESP | AUS | 0 |
NCT05620914 | Phase I | Patritumab deruxtecan | A Window of Opportunity Study of Patritumab Deruxtecan in Patients With Brain Metastases (PARAMETer) | Not yet recruiting | USA | 0 |
NCT05650879 | Phase I | ELVN-002 ELVN-002 + Trastuzumab deruxtecan Ado-trastuzumab emtansine + ELVN-002 | ELVN-002 in HER2 Mutant Non-Small Cell Lung Cancer (HER2) | Recruiting | USA | ITA | FRA | ESP | AUS | 2 |
NCT05678205 | Phase Ib/II | AB-201 Cyclophosphamide + Fludarabine | A Clinical Trial of the Safety and Anti-Tumor Activity of AB-201 in Subjects With Advanced HER2+ Solid Tumors | Not yet recruiting | USA | 1 |
NCT05704829 | Phase II | Trastuzumab deruxtecan | NeoAdjuvant Therapy With Trastuzumab-deruxtecan Versus Chemotherapy+Trastuzumab+Pertuzumab in HER2+ Early Breast Cancer (ADAPTHER2-IV) | Recruiting | DEU | 0 |
NCT05744375 | Phase II | Trastuzumab deruxtecan | Trastuzumab Deruxtecan in First-line HER2-positive Locally Advanced/MBC Patients Resistant to Trastuzumab+Pertuzumab (TRANSCENDER) | Recruiting | ESP | 0 |
NCT05748834 | Phase II | Pegylated liposomal doxorubicin + Tucatinib | Study of Tucatinib and Doxil in Participants With Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer | Recruiting | USA | 0 |
NCT05785741 | Phase Ib/II | DB-1310 | A Phase 1/2a Study of DB-1310 in Advanced/Metastatic Solid Tumors | Recruiting | USA | 1 |
NCT05800275 | Phase II | Capecitabine + Trastuzumab + Tucatinib | Capecitabine, Tucatinib, and Intrathecal Trastuzumab for Breast Cancer Patients With Leptomeningeal Disease (ETIC-LM) | Recruiting | FRA | 0 |
NCT05865990 | Phase II | Patritumab deruxtecan | HER3-DXd in Breast Cancer and NSCLC Brain Metastases and Solid Tumor Leptomeningeal Disease (TUXEDO-3) | Active, not recruiting | ESP | AUT | 0 |
NCT05894239 | Phase III | Inavolisib + Pertuzumab/trastuzumab/hyaluronidase-zzxf Pertuzumab/trastuzumab/hyaluronidase-zzxf | A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer | Recruiting | USA | TUR | POL | ITA | GBR | FRA | FIN | ESP | DEU | CAN | BRA | BEL | AUS | ARG | 11 |
NCT05900206 | Phase II | Carboplatin + Docetaxel + Pertuzumab + Trastuzumab Letrozole + Pertuzumab + Ribociclib + Trastuzumab Cyclophosphamide + Epirubicin Trastuzumab deruxtecan Carboplatin + Paclitaxel + Pertuzumab + Trastuzumab | Trastuzumab Deruxtecan Versus Standard Neoadjuvant Treatment for HER2-positive Breast Cancer (ARIADNE) | Recruiting | SWE | 0 |
NCT05955170 | Phase II | Etoposide + Trastuzumab + Tucatinib | Tucatinib in Combination With Oral Etoposide andTrastuzumab in Patients With Metastatic HER2+ Breast Cancer (TUC-TOC) | Recruiting | FRA | 0 |
NCT05957536 | Phase I | D3L-001 | A Study of D3L-001 as Monotherapy in Subjects With HER2-Positive Advanced Solid Tumors | Recruiting | USA | AUS | 1 |
NCT05982678 | Phase II | Trastuzumab deruxtecan | Basket Study for Oligo-metastatic Breast Cancer (ANISE) | Recruiting | NLD | 0 |
NCT06016387 | Phase II | Capecitabine + Trastuzumab + Tucatinib | Tucatinib With Brain and/or Spinal XRT in Patients With HER2+ Metastatic Breast Cancer and LMD | Recruiting | CAN | 0 |
NCT06068985 | Phase II | Pertuzumab/trastuzumab/hyaluronidase-zzxf | Classifying for HER2 Dependence to De-Escalate Neoadjuvant Chemotherapy in Patients With HER2+ Early Breast Cancer Undergoing HER2 Double-Blockade (CHERRY-PICK) | Not yet recruiting | BRA | 0 |
NCT06137651 | Phase I | CC-90010 + Vinorelbine | Trotabresib in Combination With Vinorelbine and Radiation Therapy for the Treatment of HER2+ Breast Cancer With Central Nervous System or Leptomeningeal Metastasis | Withdrawn | USA | 0 |
NCT06157892 | Phase Ib/II | Disitamab vedotin + Tucatinib Disitamab vedotin | A Study of Disitamab Vedotin Alone or With Other Anticancer Drugs in Solid Tumors | Recruiting | USA | ITA | GBR | ESP | CAN | AUS | 1 |
NCT06162559 | Phase I | Pertuzumab + Trastuzumab + Tucatinib | Neoadjuvant Trastuzumab, Pertuzumab and Tucatinib Without Chemotherapy in HER2-positive Breast Cancer: the TRAIN-4 Study (TRAIN-4) | Recruiting | NLD | 0 |
NCT06172127 | Phase II | Pertuzumab/trastuzumab/hyaluronidase-zzxf Trastuzumab deruxtecan | PHESGO Maintenance After T-DXd Short Induction for HER2+ Unresectable Locally Recurrent or Metastatic Breast Cancer (DEMETHER) | Recruiting | ESP | 0 |
NCT06188559 | Phase II | BB-1701 | A Study of BB-1701 in Previously Treated Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive or HER2-low Unresectable or Metastatic Breast Cancer | Recruiting | USA | 1 |
NCT06251544 | Phase I | HTR2 T cells | TRAIL-R2 and HER2 Bi-Specific Chimeric Antigen Receptor (CAR) T Cells for the Treatment of Metastatic Breast Cancer | Not yet recruiting | USA | 0 |
NCT06298084 | Phase Ib/II | Patritumab deruxtecan Olaparib + Patritumab deruxtecan | Dose-Expansion Modular Study To Explore the Safety, Tolerability, and Anti-tumor Activity of HER3- DXd Monotherapy and Combinations in Patients With Inoperable Advanced Breast Cancer (ABC) After Progression on T-DXd (ICARUSBREAST02) | Recruiting | FRA | 0 |
NCT06324357 | Phase Ib/II | Ado-trastuzumab emtansine + Zongertinib Trastuzumab deruxtecan + Zongertinib | Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib in Combination With Trastuzumab Deruxtecan or With Trastuzumab Emtansine and to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread | Recruiting | USA | ITA | ESP | BEL | 2 |
NCT06328738 | Phase I | ELVN-002 + Eribulin + Trastuzumab Capecitabine + ELVN-002 + Trastuzumab ELVN-002 + Paclitaxel + Trastuzumab Capecitabine + ELVN-002 + Oxaliplatin + Trastuzumab ELVN-002 + Fluorouracil + Leucovorin + Oxaliplatin + Trastuzumab ELVN-002 + Trastuzumab | ELVN-002 With Trastuzumab +/- Chemotherapy in HER2+ Solid Tumors, Colorectal and Breast Cancer | Recruiting | USA | NLD | ITA | FRA | ESP | BEL | 1 |
NCT06341647 | Phase I | Cyclophosphamide + Fludarabine AB-201 | Phase 1 Clinical Trial to Evaluate the Safety and Anti-Tumor Activity of AB-201 | Not yet recruiting | AUS | 0 |
NCT06348134 | Phase II | Tamoxifen Ado-trastuzumab emtansine + Docetaxel + Pertuzumab Letrozole Ado-trastuzumab emtansine Goserelin | Assessing the Efficacy and Safety of Anti-HER2 Therapy in Nigerian Women With HER2+ Breast Cancer Before and After Surgery | Not yet recruiting | USA | 0 |
NCT06435429 | Phase III | Capecitabine + ZW25 Eribulin + ZW25 Trastuzumab + Vinorelbine Gemcitabine + ZW25 Capecitabine + Trastuzumab Gemcitabine + Trastuzumab Vinorelbine + ZW25 Eribulin + Trastuzumab | A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer | Recruiting | USA | 0 |
NCT06439693 | Phase II | Docetaxel + Pertuzumab + Trastuzumab Paclitaxel + Pertuzumab + Trastuzumab Trastuzumab deruxtecan Nab-paclitaxel + Pertuzumab + Trastuzumab Pertuzumab + Trastuzumab + Tucatinib Ado-trastuzumab emtansine + Tucatinib | The SAPPHO Study: A Single-Arm, Phase II Study of Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer | Not yet recruiting | USA | 0 |
NCT06441890 | Phase II | Trastuzumab Docetaxel Paclitaxel Nab-paclitaxel Pertuzumab | BRE-10: Biomarker Optimization of Neoadjuvant Therapy in Breast Cancer (BRE-10) | Recruiting | USA | 0 |
NCT06625775 | Phase I | BBO-10203 + Trastuzumab BBO-10203 | Dose Escalation and Expansion of BBO-10203 in Advanced Solid Tumors (BREAKER-101) | Recruiting | USA | 0 |